Alexion Pharmaceuticals is a global biopharmaceutical company focused on rare diseases, with more than 5,000 employees. The company specializes in translating the complex biology of the complement system into therapeutic interventions - a domain that demands rigorous understanding of molecular pathways, bioinformatics, and large-scale data analysis to identify viable drug targets and validate mechanisms of action.
Engineering roles at Alexion operate at the intersection of drug development and systems-level biology. The complement system presents hard problems in modeling, simulation, and data integration: characterizing protein interactions, predicting therapeutic response across heterogeneous patient populations, and managing high-dimensional datasets from preclinical and clinical studies. Robotics and automation engineers may contribute to high-throughput screening platforms, laboratory automation, and assay development pipelines that accelerate the translation from target identification to candidate selection.
The company's technical domains - complement system biology, rare disease innovation, and drug development - require cross-functional collaboration between computational scientists, bench researchers, and process engineers. Alexion operates globally and states a culture organized around five values: follow the science, put patients first, play to win, do the right thing, and think entrepreneurially. For engineers, the draw is the opportunity to apply automation, data-driven methods, and systems thinking to diseases where patient populations are small and each experimental cycle carries outsized significance.